Pier Capital LLC reduced its position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 8.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 112,576 shares of the life sciences company’s stock after selling 10,728 shares during the period. Pier Capital LLC owned approximately 0.14% of Integra LifeSciences worth $5,683,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IART. LS Investment Advisors LLC raised its holdings in Integra LifeSciences by 4.6% during the second quarter. LS Investment Advisors LLC now owns 2,523 shares of the life sciences company’s stock worth $138,000 after purchasing an additional 111 shares in the last quarter. Aperio Group LLC raised its holdings in Integra LifeSciences by 16.1% during the second quarter. Aperio Group LLC now owns 20,956 shares of the life sciences company’s stock worth $1,142,000 after purchasing an additional 2,906 shares in the last quarter. US Bancorp DE grew its position in Integra LifeSciences by 2.6% during the second quarter. US Bancorp DE now owns 23,620 shares of the life sciences company’s stock worth $1,288,000 after buying an additional 593 shares during the period. Strs Ohio grew its position in Integra LifeSciences by 60.4% during the second quarter. Strs Ohio now owns 7,700 shares of the life sciences company’s stock worth $419,000 after buying an additional 2,900 shares during the period. Finally, Municipal Employees Retirement System of Michigan grew its position in Integra LifeSciences by 62.4% during the second quarter. Municipal Employees Retirement System of Michigan now owns 22,200 shares of the life sciences company’s stock worth $1,210,000 after buying an additional 8,530 shares during the period. 87.62% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have weighed in on the stock. Barclays restated an “equal weight” rating and set a $53.00 target price (up from $47.00) on shares of Integra LifeSciences in a research report on Tuesday, September 12th. Jefferies Group restated a “buy” rating on shares of Integra LifeSciences in a research report on Sunday, September 10th. Oppenheimer restated a “buy” rating and set a $60.00 target price on shares of Integra LifeSciences in a research report on Monday, September 18th. Zacks Investment Research lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Monday, October 9th. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a $50.00 target price (up from $48.00) on shares of Integra LifeSciences in a research report on Thursday, November 9th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $53.82.

In other news, VP Richard D. Gorelick sold 1,500 shares of the stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total value of $70,785.00. Following the sale, the vice president now directly owns 21,665 shares in the company, valued at $1,022,371.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Barbara B. Hill purchased 10,768 shares of the stock in a transaction dated Tuesday, October 31st. The stock was acquired at an average price of $46.66 per share, for a total transaction of $502,434.88. Following the completion of the transaction, the director now directly owns 55,540 shares of the company’s stock, valued at $2,591,496.40. The disclosure for this purchase can be found here. 21.50% of the stock is owned by corporate insiders.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ IART) opened at $48.26 on Tuesday. The company has a market cap of $3,852.46, a P/E ratio of 27.12, a PEG ratio of 2.15 and a beta of 0.65. Integra LifeSciences Holdings Corporation has a 1 year low of $38.01 and a 1 year high of $56.42. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.49 and a quick ratio of 3.39.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Thursday, October 26th. The life sciences company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.47 by ($0.02). The business had revenue of $278.83 million during the quarter, compared to analyst estimates of $286.00 million. Integra LifeSciences had a net margin of 4.52% and a return on equity of 16.35%. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.93 earnings per share. sell-side analysts predict that Integra LifeSciences Holdings Corporation will post 1.85 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.watchlistnews.com/pier-capital-llc-has-5-68-million-position-in-integra-lifesciences-holdings-corporation-iart/1744602.html.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.